红藤败酱散加减联合氟罗沙星治疗慢性盆腔炎的效果及对患者血清炎性因子水平和血液流变学指标的影响

目的 探究红藤败酱散加减联合氟罗沙星治疗慢性盆腔炎的效果及对患者血清炎性因子水平和血液流变学指标的影响.方法 选取2017年1月至2021年1月本院收治的644例慢性盆腔炎患者作为研究对象,遵循随机数字表法将其分为参照组与研究组,各322例.参照组给予氟罗沙星治疗,研究组给予红藤败酱散加减联合氟罗沙星治疗.比较两组患者的治疗效果、不良反应发生情况、病情积分、血清炎性因子水平及血液流变学指标.结果 研究组的治疗总有效率高于参照组,差异具有统计学意义(P<0.05).研究组的不良反应总发生率低于参照组,差异具有统计学意义(P<0.05).治疗前,两组的临床症状、局部体征及综合积分比较,差异无统计学意义(P>0.05);治疗后,研究组的临床症状、局部体征及综合积分均显著低于参照组,差异具有统计学意义(P<0.05).治疗前,两组的TNF-α、PCT、hs-CRP、IL-1β水平比较,差异无统计学意义(P>0.05);治疗后,研究组的TNF-α、PCT、hs-CRP、IL-1β水平均显著低于参照组,差异具有统计学意义(P<0.05).治疗前,两组的纤维蛋白原水平、红细胞压积、全血低切黏度、血浆比黏度、血沉比较,差异无统计学意义(P>0.05);治疗后,研究组的纤维蛋白原水平、红细胞压积、全血低切黏度、血浆比黏度、血沉均显著低于参照组,差异具有统计学意义(P<0.05).结论 红藤败酱散加减联合氟罗沙星治疗慢性盆腔炎的效果显著,可显著改善患者病情,降低血清炎性因子指标水平及不良反应发生率,改善血液流变学指标,值得在临床推广和应用.

Effect of modified Hongteng Baijiang powder combined with fleroxacin in the treatment of chronic pelvic inflammatory disease and its influence on serum inflammatory factors levels and hemorheological indexes of patients

Objective To explore the effect of modified Hongteng Baijiang powder combined with fleroxacin in the treatment of chronic pelvic inflammatory disease and its influences on serum inflammatory factors levels and hemorheological indexes of patients. Methods A total of 644 patients with chronic pelvic inflammatory disease treated in our hospital from January 2017 to January 2021 were selected as the research objects. The patients were divided into reference group and study group according to random number table method, with 322 cases in each group. The reference group was treated with fleroxacin, and the study group was treated with modified Hongteng Baijiang powder combined with fleroxacin.The therapeutic effect, occurrence of adverse reactions, disease score, serum inflammatory factors levels and hemorheological indexes were compared between the two groups. Results The total effective rate of treatment in the study group was higher than that in the reference group, and the difference was statistically significant(P <0.05). The total incidence of adverse reactions in the study group was lower than that in the reference group, and the difference was statistically significant(P<0.05). Before treatment, there were no significant differences in the clinical symptom, local sign and comprehensive scores between the two groups(P >0.05);after treatment, the clinical symptom, local sign and comprehensive scores in the study group were significantly lower than those in the reference group, and the differences were statistically significant(P<0.05). Before treatment, there were no significant differences in the levels of TNF-α, PCT, hs-CRP,IL-1β between the two groups(P>0.05);after treatment, the levels of TNF-α, PCT, hs-CRP, IL-1β in the study group were significantly lower than those in the reference group, and the differences were statistically significant(P<0.05). Before treatment,there were no significant differences in the fibrinogen level, hematocrit, whole blood low shear viscosity, plasma specific viscosity and erythrocyte sedimentation rate between the two groups(P>0.05);after treatment, fibrinogen level, hematocrit, whole blood low shear viscosity, plasma specific viscosity and erythrocyte sedimentation rate in the study group were lower than those in the reference group, and the differences were statistically significant(P<0.05). Conclusion Modified Hongteng Baijiang powder combined with fleroxacin in the treatment of chronic pelvic inflammatory disease has a significant effect, it can significantly improve the patients’ condition, reduce the levels of serum inflammatory factors and the incidence of adverse reactions, and improve hemorheological indexes, which is worthy of clinical promotion and application.